AR099416A1 - Terapia combinada para la hipertensión resistente - Google Patents
Terapia combinada para la hipertensión resistenteInfo
- Publication number
- AR099416A1 AR099416A1 ARP150100429A ARP150100429A AR099416A1 AR 099416 A1 AR099416 A1 AR 099416A1 AR P150100429 A ARP150100429 A AR P150100429A AR P150100429 A ARP150100429 A AR P150100429A AR 099416 A1 AR099416 A1 AR 099416A1
- Authority
- AR
- Argentina
- Prior art keywords
- resistant hypertension
- combined therapy
- patient
- methyl
- formula
- Prior art date
Links
- 208000015658 resistant hypertension Diseases 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 abstract 1
- -1 3-fluoro-6H-benzo [c ] [2] benzoxepin-yl-ylidene Chemical group 0.000 abstract 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004202 carbamide Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 abstract 1
- 229960000835 tadalafil Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicación 1: Un método de tratamiento de la hipertensión resistente en un paciente, caracterizado porque comprende administrar a un paciente en necesidad de tal tratamiento una cantidad eficaz del compuesto [5-[(E)-(3-fluoro-6H-benzo[c][2]benzoxepin-il-ilideno)metil]-1-[(1R)-1-metil-2-morfolino-etil]benzimidazol-2-il]urea, representado estructuralmente por la fórmula (1) o una sal farmacéuticamente aceptable del mismo, en combinación con una cantidad eficaz de Tadalafil, representado estructuralmente por la fórmula (2).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461946061P | 2014-02-28 | 2014-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR099416A1 true AR099416A1 (es) | 2016-07-20 |
Family
ID=52684674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150100429A AR099416A1 (es) | 2014-02-28 | 2015-02-12 | Terapia combinada para la hipertensión resistente |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR099416A1 (es) |
| WO (1) | WO2015130568A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110790764B (zh) * | 2019-11-27 | 2021-04-06 | 四川省通园制药集团有限公司 | 一种一锅法制备他达拉非的方法 |
| CN111253399A (zh) * | 2020-03-30 | 2020-06-09 | 苏州弘森药业股份有限公司 | 一种他达拉非原料药的生产工艺 |
| CN113582992A (zh) * | 2021-06-11 | 2021-11-02 | 山东罗欣药业集团股份有限公司 | 一种磷酸二酯酶抑制剂的制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| US6821975B1 (en) | 1999-08-03 | 2004-11-23 | Lilly Icos Llc | Beta-carboline drug products |
| BR0012863A (pt) | 1999-08-03 | 2002-04-16 | Lilly Icos Llc | Composições farmacêuticas de "beta"-carbolina |
| JP2005536567A (ja) | 2002-07-31 | 2005-12-02 | リリー アイコス リミテッド ライアビリティ カンパニー | ピクテ−スペングラー反応の変法およびその産物 |
| US20070196510A1 (en) | 2006-02-17 | 2007-08-23 | Gerber Michael J | Method for treating resistant hypertension |
| PE20091057A1 (es) | 2007-12-19 | 2009-07-20 | Lilly Co Eli | Antagonistas del receptor mineralcorticoide y metodos de uso |
-
2015
- 2015-02-12 AR ARP150100429A patent/AR099416A1/es unknown
- 2015-02-20 WO PCT/US2015/016818 patent/WO2015130568A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015130568A1 (en) | 2015-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
| AR101740A1 (es) | Terapia de combinación y composiciones | |
| NZ730809A (en) | Methods for treating filoviridae virus infections | |
| ES2721001T3 (es) | Derivado de isoindolina, y composiciones y métodos para tratar una enfermedad neurodegenerativa | |
| UA117451C2 (uk) | Терапевтично активні сполуки і способи їх застосування | |
| AR094970A1 (es) | Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer | |
| CR20150416A (es) | Inhibidores de cdc7 | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| EA201691481A1 (ru) | ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ | |
| AR103680A1 (es) | Inhibidores selectivos de bace1 | |
| CR20140086A (es) | Tratamientos de combinación para hepatitis c | |
| CL2017000050A1 (es) | Terapia de combinación para el cáncer | |
| MX2017003780A (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| NI201800071A (es) | Compuestos de isoindol | |
| CL2019002325A1 (es) | Combinaciones farmacéuticas para tratar cáncer. | |
| AR092103A1 (es) | Laquinimod en el tratamiento de los trastornos mediados por el receptor de canabinoides del tipo 1 (cb1) | |
| SV2018005701A (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
| AR099416A1 (es) | Terapia combinada para la hipertensión resistente | |
| MX2017003140A (es) | Tratamiento de los sintomas asociados a terapia privacion de androgenos. | |
| MX2018001684A (es) | Metodo de curacion de heridas. | |
| ES2721003T3 (es) | Utilización de ácido 1, 3 - propano disulfónico o sales farmacéuticamente aceptables del mismo para el tratamiento de la sarcoidosis | |
| AR117290A1 (es) | Enfoque de tratamiento de cáncer mediante inmunomodulación | |
| AR115865A2 (es) | Compuestos terapéuticos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |